Clinical Trial Searching for the Genetic Link to a Mesothelioma Diagnosis
In a clinical trial that asks the question, “Do Your Genes Put You at a Higher Risk of Developing Mesothelioma?” researchers led by Jill Ohar MD of Wake Forest University are actively recruiting patients of the New York University School of Medicine, Memorial Sloan Kettering Cancer Center and Wake Forest University Health Sciences who suffer from mesothelioma. The researchers are investigating the possibility that a person’s genes put a person at a higher risk of developing mesothelioma.
Pleural mesothelioma is a form of lung cancer that is almost always caused by asbestos exposure and is found in the outer lining of the lungs called the mesothelium. According to the clinical trial information, however, nearly 27 million individuals in the US were exposed to asbestos in the work place between 1940 and 1979, but just 3,000 new cases of mesothelioma are diagnosed each year. So what makes those people susceptible to the disease?
During the trial, the researchers will examine genes from DNA isolated from patients’ blood. In addition, the study will examine the impact of environmental and work exposures and family history of common cancers on the development of mesothelioma. The biomarkers in this study will identify how a person’s body processes frequently encountered environmental pollutants, but will not tell about chromosomes, specific diseases, or other potential health problems.
The goal is to enroll 1,000 mesothelioma patients. The anticipated completion date is December 2014. For more information, or to enroll in the study, see Do Your Genes Put You at a Higher Risk of Developing Mesothelioma.
Malignant mesothelioma clinical trials continue to be one of the best options for patients struggling to find a new, effective treatment. Mesothelioma is being fought internationally, and clinical trials are offered throughout the world. According to clinicaltrials.gov, there are currently 23 open studies for malignant mesothelioma being conducted worldwide. Trial sites include the United States, Switzerland, the Netherlands and Italy.